UBX1967

About Unity Biotechnology

Unity Biotechnology is pioneering a novel approach to treating age-related diseases by targeting senescent cells, which accumulate with age and contribute to tissue dysfunction and chronic inflammation. The company's core technology focuses on inhibiting Bcl-xL, a pro-survival protein in senescent cells, to induce their apoptosis. Its most advanced candidate, UBX1325, has shown promising results in mid-stage trials for retinal diseases, positioning Unity at the forefront of the emerging senolytic therapeutics field. The company is publicly traded and continues to advance its pipeline while exploring new indications for its platform.

Therapeutic Areas